We only have this paper's title and publication details.
Read it at the sourceCaptured external expert commentary on this paper, strongest first. Original sources are linked where available.
“High blood pressure is the most common and most modifiable risk factor for heart disease. By addressing individual risks earlier and offering more tailored strategies across the lifespan, the 2025 guideline aims to aid clinicians in helping more people manage their blood pressure and reduce the toll of heart disease, kidney disease, Type 2 diabetes.”
“One of the major new recommendations in the 2025 Guideline is the emphasis on screening for hyperaldosteronism in all patients with resistant hypertension, regardless of their serum potassium levels. This reflects the growing evidence that up to one-third of patients with resistant hypertension have hyperaldosteronism and could benefit from targeted interventions.”
“This broader, more personalized approach gives clinicians a better idea of which people with hypertension would benefit most from treatment.”
No takes yet. Share an insight, caveat, or question.
Biola et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: